JPMorgan Chase & Co. Reaffirms “Neutral” Rating for Insulet (NASDAQ:PODD)

Insulet (NASDAQ:PODD)‘s stock had its “neutral” rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Thursday, MarketBeat reports. They currently have a $152.00 price target on the medical instruments supplier’s stock, down from their prior price target of $275.00. JPMorgan Chase & Co.‘s target price points to a potential upside of 7.67% from the company’s current price.

Other equities analysts have also issued research reports about the company. Robert W. Baird lowered their price objective on Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Evercore set a $180.00 price target on Insulet in a research report on Monday, July 6th. Royal Bank Of Canada cut their price objective on shares of Insulet from $280.00 to $245.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Insulet in a research report on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 target price for the company. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $195.40.

Insulet Price Performance

Shares of Insulet stock opened at $141.17 on Thursday. The company has a quick ratio of 1.81, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $9.79 billion, a price-to-earnings ratio of 26.39, a price-to-earnings-growth ratio of 1.03 and a beta of 1.10. Insulet has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a 50-day simple moving average of $155.42 and a two-hundred day simple moving average of $193.60.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same quarter in the prior year, the business posted $1.17 EPS. The business’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts forecast that Insulet will post 6.51 EPS for the current year.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC increased its holdings in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet in the 4th quarter valued at $26,000. DV Equities LLC acquired a new stake in shares of Insulet during the 4th quarter valued at $28,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet during the 4th quarter valued at $28,000. Finally, Mcguire Capital Advisors Inc. bought a new stake in Insulet during the 4th quarter worth $29,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported strong second-quarter results, with revenue of $801.7 million, up 23.5% year over year, and adjusted EPS of $1.66 versus the $1.47 consensus estimate. The results indicate continued demand for the Omnipod platform despite emerging retention issues. Insulet Corporation Q2 2026 Earnings Call Summary
• Neutral Sentiment: Several law firms are seeking lead plaintiffs for a federal securities class action covering investors who purchased PODD shares between February 21, 2025, and May 26, 2026. The lead-plaintiff deadline is August 31, 2026; the allegations have not been proven. Pomerantz class-action announcement
• Negative Sentiment: Insulet reduced its 2026 revenue outlook after identifying weaker-than-expected retention among Type 2 diabetes users. Investors are concerned that the issue could temper Omnipod adoption and second-half growth, despite management maintaining that the broader growth opportunity remains intact. Insulet cuts 2026 revenue outlook
• Negative Sentiment: Analysts sharply cut their valuations following the guidance reduction. TD Cowen lowered its price target to $144 with a hold rating, UBS reduced its target to $150 with a neutral rating, JPMorgan cut its target to $152, and Leerink downgraded PODD to market perform. Benchmark and Stifel retained buy ratings but also lowered their targets. Analysts slash Insulet forecasts
• Negative Sentiment: Investor concerns also include two recent Omnipod recalls or voluntary medical-device corrections, which have raised questions about manufacturing quality, potential regulatory scrutiny and reputational damage. The newly filed lawsuit alleges securities-law violations related to these issues and the company’s disclosures. PODD shareholder alert

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.